Figure 2From: Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vsobservation with predefined second-line treatment after cisplatin–gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study Multivariate probabilistic sensitivity analysis (results of a 10 000-replication simulation). A. Gemcitabine v observation, B. Erlotinib v observation.Back to article page